SER Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
-100.0%
130.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
-100.0%
130.0K
Operating Expenses
6.8M
+8.0%
6.3M
+1.2%
6.2M
-2.9%
6.4M
+12.2%
5.7M
R&D
3.8M
+19.3%
3.2M
-5.9%
3.4M
-6.8%
3.7M
+15.8%
3.2M
SG&A
3.0M
-3.7%
3.1M
+9.8%
2.8M
+2.4%
2.7M
+7.8%
2.5M
Operating Income
-6784000
-8.0%
-6280000
-1.2%
-6207000
+2.9%
-6392000
-14.9%
-5565000
EBITDA
-6766000
-8.0%
-6262000
-1.3%
-6183000
+3.0%
-6376000
-14.9%
-5549000
Net Income
-6356000
+7.9%
-6898000
-106.8%
-3336000
+27.4%
-4595000
+28.9%
-6462000
EPS (Basic)
$-0.55
+5.2%
$-0.58
-70.6%
$-0.34
+24.4%
$-0.45
+31.8%
$-0.66
EPS (Diluted)
$-0.55
+5.2%
$-0.58
-70.6%
$-0.34
+24.4%
$-0.45
+31.8%
$-0.66
Shares (Diluted)
16.4M
+36.0%
12.0M
+13.0%
10.7M
+3.1%
10.3M
+3.3%
10.0M
Serina Therapeutics (SER) โ€” Financials